Predictors of Low Patient Activation When Initiating C1 Esterase Inhibitor Therapy for Hereditary Angioedema

By Lash Group |

Hereditary Angioedema (HAE) is a very rare and potentially life-threatening genetic condition. HAE occurs in about 1 in 10,000 to 1 in 50,000 people. Symptoms include episodes of edema (swelling) in various parts of the body including the hands, feet, face, and airway. Swelling can occur at any time and if located within the airway, the mortality rate was reportedly as high as 30% without proper, quick treatment.
Patients with this rare disease have a defect in the gene that controls a blood protein called C1 inhibitor. Because of the defect to this gene, a biochemical imbalance can occur and produce unwanted peptides that induce the capillaries to release fluids into the surrounding tissue; thus causing edema. Learn more about predictors of low patient activation when initiating C1 esterase inhibitor therapy for hereditary angioedema.